Insilico Medicine IP Ltd. has identified small-molecule inhibitors of ubiquitin carboxyl-terminal hydrolase 1 (USP1) reported to be useful for the treatment of cancer.
Insilico Medicine has licensed TaiGen Biotechnology exclusive rights in the Greater China area to develop, commercialize, and sub-license ISM4808, an AI-driven potential best-in-class oral PHD ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback